On Aug. 4, 2020, Cocrystal Pharma announced the publication of preclinical animal studies of coronavirus antiviral compounds in the medical journal, Science Translational Medicine. Cocrystal initiated its preclinical studies of COVID-19 inhibitors during second quarter of 2020.

The Company had identified additional inhibitors using its proprietary platform technology and anticipated the selection of its lead preclinical molecule by the end of 2020.